The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: Evidence for specific inhibition of P2Y12 receptors by prasugrel

Biochemical Pharmacology

Volumn 74, Issue 7, 2007, Pages 1003-1009

  Hashimoto, Masami ^a   Sugidachi, Atsuhiro ^a   Isobe, Takashi ^a   Niitsu, Yoichi ^a   Ogawa, Taketoshi ^a   Jakubowski, Joseph A ^b   Asai, Fumitoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

ADP; Knockout mouse; P2Y12 receptor; Platelet; Prasugrel

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL; PURINE P2Y12 RECEPTOR; THROMBOCYTE SLOWING FACTOR; ANTITHROMBOCYTIC AGENT; MEMBRANE PROTEIN; P2RY12 PROTEIN, MOUSE; PIPERAZINE DERIVATIVE; PURINE P2 RECEPTOR; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RECEPTOR AFFINITY; REGULATORY MECHANISM; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; WILD TYPE; ANIMAL; C57BL MOUSE; DRUG EFFECT; GENE DELETION; GENETICS; METABOLISM; SEXUAL DEVELOPMENT; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; FEMALE; GENE DELETION; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; SEX CHARACTERISTICS; THIOPHENES;

EID: 34548010822     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.027     Document Type: Article

References (31)

1. Zucker M.B., and Nachmias V.T. Platelet activation. Arteriosclerosis 5 (1985) 2-18
2. 12 receptor. Curr Pharm Des 12 (2006) 1255-1259
3. Kahner B.N., Shankar H., Murugappan S., Prasad G.L., and Kunapuli S.P. Nucleotide receptor signaling in platelets. J Thromb Haemost 4 (2006) 2317-2326
4. Jin J., Daniel J.L., and Kunapuli S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273 (1998) 2030-2034
5. Leon C., Ravanat C., Freund M., Cazenave J.P., and Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 23 (2003) 1941-1947
6. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 (2001) 202-207
7. Zhang F.L., Luo L., Gustafson E., Lachowicz J., Smith M., Qiao X., et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 276 (2001) 8608-8615
8. Takasaki J., Kamohara M., Saito T., Matsumoto M., Matsumoto S., Ohishi T., et al. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol 60 (2001) 432-439
9. Cosemans J.M., Munnix I.C., Wetzker R., Heller R., Jackson S.P., and Heemskerk J.W. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 108 (2006) 3045-3052
10. Kamae T., Shiraga M., Kashiwagi H., Kato H., Tadokoro S., Kurata Y., et al. Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation. J Thromb Haemost 4 (2006) 1379-1387
11. Huang J., Driscoll E.M., Gonzales M.L., Park A.M., and Lucchesi B.R. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp Ther 295 (2000) 492-499
12. van Gestel M.A., Heemskerk J.W., Slaaf D.W., Heijnen V.V., Reneman R.S., and oude Egbrink M.G. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 23 (2003) 518-523 [Epub 2003 Jan 23]
13. Foster C.J., Prosser D.M., Agans J.M., Zhai Y., Smith M.D., Lachowicz J.E., et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107 (2001) 1591-1598
14. André P., Delaney S.M., LaRocca T., Vincent D., DeGuzman F., Jurek M., et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112 (2003) 398-406
15. Wiviott S.D., Antman E.M., Gibson C.M., Montalescot G., Riesmeyer J., Weerakkody G., et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Am Heart J 152 (2006) 627-635
16. Sugidachi A., Asai F., Ogawa T., Inoue T., and Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129 (2000) 1439-1446
17. 12 receptor antagonist activity. Semin Thromb Hemost 31 (2005) 184-194
18. 12 inhibitor: a single ascending dose study in healthy humans. Platelets 17 (2006) 209-217
19. Jakubowski J.A., Payne C.D., Weerakkody G.J., Brandt J.T., Farid N.A., Li Y.G., et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 49 (2007) 167-173
20. i-linked P2T antagonist, CS-747. Br J Pharmacol 132 (2001) 47-54
21. 12 receptor inhibitor. Thromb Haemost 94 (2005) 593-598
22. Brandt J.T., Payne C.D., Wiviott S.D., Weerakkody G.J., Farid N.A., Small D.S., et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153 (2007) e9-e16
23. Jernberg T., Payne C.D., Winters K.J., Darstein C., Brandt J.T., Jakubowski J.A., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006) 1166-1173
24. Jakubowski J.A., Payne C.D., Brandt J.T., Weerakkody G.J., Farid N.A., Small D.S., et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 47 (2006) 377-384
25. 12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 63 (2007) 421-430
26. Maffrand J.P., Bernat A., Delebassee D., Defreyn G., Cazenave J.P., and Gordon J.L. ADP plays a key role in thrombogenesis in rats. Thromb Haemost 59 (1998) 225-230
27. Kunapuli S.P., Dorsam R.T., Kim S., and Quinton T.M. Platelet purinergic receptors. Curr Opin Pharmacol 3 (2003) 175-180
28. Leon C., Hechler B., Freund M., Eckly A., Vial C., Ohlmann P., et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 104 (1999) 1731-1737
29. Hechler B., Leon C., Vial C., Vigne P., Frelin C., Cazenave J.P., et al. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 92 (1998) 152-159
30. Fabre J.E., Nguyen M., Latour A., Keifer J.A., Audoly L.P., Coffman T.M., et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 5 (1999) 1199-1202
31. Emms H., and Lewis G.P. The roles of prostaglandin endoperoxides, thromboxane A2 and adenosine diphosphate in collagen-induced aggregation in man and the rat. Br J Pharmacol 87 (1986) 109-115